Abstract | INTRODUCTION: OBJECTIVES: PATIENTS AND METHODS: We retrospectively analyzed the course, the efficacy and safety of rituximab administered at a dose lower than average in lymphoma treatment protocol (median = 1.0 g). The drug was used only in patients who presented resistance to the standard treatment with cyclophosphamide, or in whom such treatment was impossible. Disease activity was evaluated using Birmingham Vasculitis Activity Score and disease remission was defined as score 0. RESULTS: Out of the twelve patients who received RTX induction doses (period 07. 2009-07.2014), remission was achieved in the eleven (92%). Averaged observation period was 7.5 months (median). The total B-cell depletion was observed in all treated with induction scheme. During further follow-up, disease relapse in 2 patients was observed. One patient achieved remission again after re use of rituximab. The second patient died in the course of diffuse alveolar hemorrhage. In these patients, recurrence was observed respectively after 42 and 56 months of follow-up. CONCLUSIONS:
|
Authors | Katarzyna Wawrzycka-Adamczyk, Anna Zugaj, Anna Włudarczyk, Joanna Kosałka, Jan Sznajd, Stanisława Bazan-Socha, Jacek Musiał |
Journal | Przeglad lekarski
(Przegl Lek)
Vol. 71
Issue 12
Pg. 663-5
( 2014)
ISSN: 0033-2240 [Print] Poland |
PMID | 25951692
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Immunologic Factors
- Rituximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Granulomatosis with Polyangiitis
(drug therapy)
- Humans
- Immunologic Factors
(administration & dosage)
- Male
- Middle Aged
- Recurrence
- Remission Induction
- Retrospective Studies
- Rituximab
- Treatment Outcome
- Young Adult
|